Collect Product
Product Details
Synonyms
AITR, GITR, TNFRSF18, CD357
Source
Human GITR, Fc Tag (GIR-H5254) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Glu 161 (Accession # Q9Y5U5-1).
Predicted N-terminus: Gln 26
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 41.0 kDa. The protein migrates as 45-47 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Human GITR, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human GITR, Fc Tag (Cat. No. GIR-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human GITR Ligand, Avitag,Fc Tag (Cat. No. GIL-H82F8) with a linear range of 4-63 ng/mL (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Glucocorticoid-induced tumor necrosis factor receptor-related protein
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
4 Details
- Highest R&D Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
